Inspira Technologies develops its innovative AI-powered HYLA
technology with advanced blood testing capability, enabling
continuous monitoring of tissue oxygenation and early hypoxia
detection; Company expects to release preliminary clinical results
for the sensor in the near future
RA'ANANA, Israel, Feb. 5, 2025
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq:
IINN) ("Inspira" or the "Company"), a pioneer in breakthrough
life-support technology, today announced the integration of a
next-generation oxygenation indicator into its AI-powered HYLA™
blood sensor technology, designed to enable the rapid detection of
critical oxygen-related conditions without the need for
intermittent blood draws.
We believe that the integration of this advanced indicator
represents a significant enhancement in critical care monitoring.
The technology is designed to provide data through real-time and
continuous monitoring of oxygenation therapy, enabling the rapid
detection of tissue hypoxia and the early warning of respiratory
complications. The advanced AI-powered system is designed to
indicate the level of lung function and to monitor vital blood
parameters, positioning HYLA as a potential game-changer in the
$2.5 billion point-of-care testing
and arterial blood gas analyzer market.
Clinical validation of the enhanced HYLA blood sensor, with its
new oxygenation indicator, is currently underway at Sheba Medical
Center, ranked among the world's top 10 smart hospitals by
Newsweek. The Company is optimistic about the ongoing evaluations
and expects to share preliminary clinical results in the near
future. The non-invasive technology utilizes sophisticated optical
sensors and machine-learning algorithms to deliver continuous
monitoring of blood parameters and oxygen levels, with a U.S. Food
and Drug Administration ("FDA") submission for regulatory clearance
anticipated for the second half of 2025.
"This advancement marks an important step in transforming
critical care monitoring," said Dagi Ben-Noon, chief executive
officer of Inspira. "The integration of this new oxygenation
indicator into HYLA will enable healthcare providers to monitor and
respond to changes in tissue oxygenation in real-time. We continue
to advance in our clinical evaluation program and look forward to
sharing preliminary clinical results with the public in the near
future, which we hope will further validate the HYLA's unique
technological offering and superiority over traditional blood
sensors in the market."
The addition of advanced oxygenation monitoring capabilities
further strengthens HYLA's position as a comprehensive blood
monitoring solution. When combined with the FDA-cleared INSPIRA
ART100 system, this technology aims to provide a more complete
approach to patient care by enabling continuous, non-invasive
monitoring while maintaining consciousness during treatment.
About Inspira Technologies
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to revolutionize the
$19 billion mechanical ventilation
market. With 20 million intensive care unit patients with acute
respiratory failure each year, many of whom rely on mechanical
ventilators, the INSPIRA ART offers a potential alternative by
elevating and stabilizing decreasing oxygen saturation levels in
minutes without a ventilator, with patients being awake during
treatment. The INSPIRA ART is being equipped with a clip-on HYLA™
blood sensor, a real-time continuous blood monitoring technology,
aiming to alert physicians of changes in a patient's condition
without the need for intermittent actual blood samples, aiming to
support physicians in making informed decisions.
For more information, visit:
https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements are based on the current expectations of
the management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
For example, the Company is using forward-looking statements when
it discusses the prospective benefits and function of the HYLA
blood sensor, the belief that the integration of this advanced
indicator represents a significant enhancement in critical care
monitoring, the prospective FDA regulatory clearance submission,
the belief that this development marks an important step in
transforming critical care monitoring, the expected release of
preliminary clinical results, the belief that the integration of
this new oxygenation indicator into HYLA enables healthcare
providers to monitor and respond to changes in tissue oxygenation
in real-time, and the belief that the addition of advanced
oxygenation monitoring capabilities further strengthens HYLA's
position as a comprehensive blood monitoring solution. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023,
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies – Media
Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Capital Markets & Investor Contact
Arx | Capital
Markets Advisors
North American Equities Desk
inspira@arxadvisory.com
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-technologies-integrates-new-oxygenation-indicator-into-ai-powered-hyla-blood-sensor-302368820.html
SOURCE Inspira Technologies
